SRTA Form 4: Insider exercises 55,555 options at $0.18
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Strata Critical Medical (SRTA) reported an insider transaction: Co‑CEO and General Counsel Melissa M. Tomkiel exercised stock options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.
Following the transaction, she beneficially owned 1,214,816 shares directly, and held 360,294 stock options outstanding. The option grant was originally exercisable from 05/07/2021 and expires 07/28/2030.
Positive
- None.
Negative
- None.
Insider Trade Summary
55,555 shares exercised/converted
Mixed
2 txns
Insider
Tomkiel Melissa M.
Role
Co-CEO and General Counsel
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option (right to buy) | 55,555 | $0.00 | -- |
| Exercise | Class A common stock, $0.0001 par value per share | 55,555 | $0.18 | $10K |
Holdings After Transaction:
Stock Option (right to buy) — 360,294 shares (Direct);
Class A common stock, $0.0001 par value per share — 1,214,816 shares (Direct)
Footnotes (1)
FAQ
What did SRTA disclose in this Form 4?
Co‑CEO and General Counsel Melissa M. Tomkiel exercised options (code M) for 55,555 Class A shares at $0.18 on 10/10/2025.
What options remain for the insider at SRTA?
She held 360,294 stock options outstanding after the reported transaction.
What are the key terms of the exercised SRTA option?
The option had an exercise price of $0.18, was exercisable from 05/07/2021, and expires on 07/28/2030.
Who is the reporting person in SRTA’s Form 4?
The reporting person is Melissa M. Tomkiel, SRTA’s Co‑CEO and General Counsel, who also serves as a Director.
What was the transaction code in SRTA’s Form 4 and what does it indicate?
The transaction code is M, indicating an option exercise resulting in acquisition of underlying shares.